Suggested Remit: To appraise the clinical and cost effectiveness of rivogenlecleucel within its marketing authorisation for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant.
Topic is suspended
 
Status Suspended
Process STA 2018
ID number 1601

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
12 February 2021 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant. For information, the company has advised it has paused its effort to pursue a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
12 February 2021 Suspended. Topic is suspended
24 January 2020 In progress. Topic is in progress
13 May 2019 (10:00) Scoping workshop (Manchester)
20 March 2019 - 17 April 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance